Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Camp4 Therapeutics (CAMP) EBITDA Margin (2023 - 2025)

Camp4 Therapeutics (CAMP) has disclosed EBITDA Margin for 3 consecutive years, with 11575.86% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 953921.0% to 11575.86% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2298.54% through Dec 2025, up 564486.0% year-over-year, with the annual reading at 2298.54% for FY2025, 564486.0% up from the prior year.
  • EBITDA Margin hit 11575.86% in Q4 2025 for Camp4 Therapeutics, down from 1899.25% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 840.81% in Q2 2025 to a low of 11575.86% in Q4 2025.
  • Historically, EBITDA Margin has averaged 3523.89% across 3 years, with a median of 1967.95% in 2025.
  • Biggest YoY gain for EBITDA Margin was -953921bps in 2025; the steepest drop was -953921bps in 2025.
  • Year by year, EBITDA Margin stood at 3341.71% in 2023, then surged by 39bps to 2036.66% in 2024, then tumbled by -468bps to 11575.86% in 2025.
  • Business Quant data shows EBITDA Margin for CAMP at 11575.86% in Q4 2025, 1899.25% in Q3 2025, and 840.81% in Q2 2025.